Multiple Sclerosis and Neuroimmunology Research
We are deeply committed to clinical and laboratory research. As a world leader, we are engaged in numerous clinical trials investigating the effect of various new treatments targeting not only the disease process but also its symptomatology.
An important part of our clinical research is our image-processing and OCT laboratories; one of the few in the country. Following the tradition established by our late Chair and director, Dr. Omar Khan, our research focuses on the use of novel MRI technology for early disease detection and to better understand the demyelinating pathology and promote new therapeutic approaches. Our goal is to achieve neuro repair and neuroprotection, minimize the disabling effect of the disease and contribute to a better quality of life for individuals living with MS. Explore our research at the MR Core Research Facility at https://mrc.wayne.edu/ and our team https://mrc.wayne.edu/faculty
The Neuroimaging and Neurorehabilitation Laboratory (NNL) is a foundational component of our Multiple Sclerosis and Neuroimmunology Research program by advancing rehabilitation-focused neuroscience through state‑of‑the‑art imaging and quantitative assessment tools. The lab develops innovative strategies to address both motor and cognitive decline in individuals with neurodegenerative diseases (e.g., multiple sclerosis) by integrating structural neuroimaging, functional measures, and novel rehabilitation paradigms. Its work enhances our understanding of how motor and cognitive systems interact, enabling the design of targeted interventions that support recovery, promote neuroplasticity, and improve overall functional outcomes for people living with MS.
Our research has been funded by the National Institute of Health, National MS Society, the Sastry Family Foundation and pharmaceutical companies.
Clinical Trials
Below is a table of treatment trials that we are currently conducting as of March 2026:
| Name of Study | Open Since |
|---|---|
| Multiple Sclerosis | |
| An Open-label, Multicenter Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients with Relapsing Multiple Sclerosis Receiving Treatment with Ocrelizumab | 2020 |
| An Observational Study of Ocrelizumab-Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies | 2020 |
| An Open-label, Single arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects with Relapsing Multiple Sclerosis | 2019 |
| A Phase III Multicenter, Randomized Double-blind, Double-dummy, Parallel-grouop Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis. | 2022 |
| Seizure | |
| New-onset Refractory Status Epilepticus (NORSE) | 2020 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures | 2025 |
| A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | 2024 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | 2024 |
| Myasthenia Gravis | |
| A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Mild to Severe Generalized Myasthenia Gravis | 2025 |
| A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-label Remibrutinib | 2024 |
| Epilepsy | |
| SAFETY AND THERAPEUTIC MEASURES OF TRANSCRANIAL CATHODAL DIRECT CURRENT STIMULATION (TDCS) IN PATIENTS WITH REFRACTORY FOCAL EPILEPSY | 2023 |
| An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants with Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | 2024 |
| A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy | 2024 |
| Neuromyelitis Optica | |
| A long-term, open-label, low-interventional safety study of inebilizumab in the treatment of NMOSD (N-MOmentum LT) | 2024 |
| Stroke | |
| Efficacy and Safety of Milvexian Oral Drug on Stroke Patients | 2024 |
| CIPD | |
| A Phase 2b, Multi-center, Randomized, Double-blind, Placebocontrolled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2025 |